[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hypertensive-heart-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hypertensive-heart-disease":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,46,72],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100547562","cardiomyopathies-and-heart-muscle-diseases-cardiac-imaging-in-the-evaluation-of-myocardial-fibrosis-transition-100547562",false,"NCT06409585","Cardiomyopathies and Heart Muscle Diseases: Cardiac Imaging in the Evaluation of Myocardial Fibrosis Transition","CHIEFTain","Inclusion Criteria:\n\nHFpEF cohort\n\n* Male or female between 30 to 90 years old\n* Provision of informed consent prior to any study specific procedures\n* Patients with symptomatic heart failure with preserved ejection fraction as defined by the presence of heart failure symptoms (dyspnoea, reduced exercise tolerance, fatigue), signs (elevated jugular venous pressure, pulmonary crackles, peripheral oedema) as well as echocardiographic features (preserved left ventricular systolic function (\\>50%) and reduced diastolic function with septal e' \\\u003C7cm\u002Fs or lateral e' \\\u003C10cm\u002Fs).\n\nHypertrophic cardiomyopathy cohort\n\n* Male or female between 30 to 90 years old\n* Provision of informed consent prior to any study specific procedures\n* Established diagnosis of hypertrophic cardiomyopathy: left ventricular wall thickness \\>15mm by any imaging modality without a loading condition to explain the hypertrophy OR\n* Left ventricular wall thickness of \\>13 mm by any imaging modality in the presence of a genetic or non-genetic component, supported by other features including family history, non-cardiac symptoms, ECG changes and laboratory tests.\n\nHypertensive heart disease cohort\n\n* Male or female between 30 to 90 years old\n* Provision of informed consent prior to any study specific procedures\n* Diagnosis of essential hypertension for at least 1 year with evidence of left ventricular hypertrophy on echocardiography (left ventricular mass index \\>98 g\u002Fm2 and relative wall thickness \\>0.42)\n\nArrhythmogenic cardiomyopathy\n\n* Male or female between 30 to 90 years old\n* Provision of informed consent prior to any study specific procedures\n* Diagnosis of arrhythmogenic right ventricular cardiomyopathy based on the International Task Force 2010 criteria\n\nMyocarditis cohort\n\n* Male or female between 30 to 90 years old\n* Provision of informed consent prior to any study specific procedures\n* Diagnosis of myocarditis in the past month defined with the following features\n\n  * Chest pain\n  * Evidence of pericarditis (pericardial rub, ST- segment elevation or pericardial effusion)\n  * Elevated serum troponin\n  * Unobstructed coronary arteries on coronary angiogram OR\n  * Cardiac magnetic resonance imaging evidence of myocarditis (subepicardial or mid-wall late gadolinium enhancement\n\nTakotsubo cardiomyopathy cohort\n\n* Male or female between 30 to 90 years old\n* Provision of informed consent prior to any study specific procedures\n* Diagnosis of takotsubo cardiomyopathy in the past month as defined by European Society of Cardiology guidelines 2018\n\nCardiac sarcoidosis cohort\n\n* Male or female between 30 to 90 years old\n* Provision of informed consent prior to any study specific procedures\n* Diagnosis of cardiac sarcoidosis for at least 1 year based on expert consensus opinion with\n\n  * Histological diagnosis from a myocardial biopsy OR\n  * Histological diagnosis of extra-cardiac sarcoid AND\n\nOne or more of following is present\n\n* Steroid +\u002F- immunosuppressant responsive cardiomyopathy or heart block\n* Unexplained reduced LVEF (\\\u003C40%)\n* Unexplained sustained (spontaneous or induced) VT\n* Mobitz type II 2nd degree heart block or 3rd degree heart block\n* Patchy uptake on dedicated cardiac PET (in a pattern consistent with CS)\n* Late Gadolinium Enhancement on CMR (in a pattern consistent with CS)\n* Positive gallium uptake (in a pattern consistent with CS) AND\n* Other causes for the cardiac manifestation(s) have been reasonably excluded\n\nExclusion Criteria:\n\n* Inability or unwilling to give informed consent.\n* History of claustrophobia or inability to tolerate supine position for the PET\u002FMR or PET\u002FCT scans.\n* Impaired renal function with eGFR of \\\u003C30 mL\u002Fmin\u002F1.73 m2.\n* Women who are pregnant or breastfeeding.\n* Iodine or gadolinium contrast allergy\n* Contra-indication to CT scanning",true,"ALL","30 Years","90 Years",{"count":21,"type":22},290,"ESTIMATED","OBSERVATIONAL","Heart scarring, also known as fibrosis, plays a major role in a lot of heart muscle abnormalities. These abnormalities of the heart muscle can lead to major issues such as symptoms of heart failure, dangerous heart rhythm disturbances and even death. However, a lot of these conditions are still not fully understood and treatment options are limited. We here aim to use a new radioactive dye called 68Ga-FAPI to identify patterns and the activity of heart muscle scarring. This radioactive dye is being used in humans particularly in identifying and monitoring cancers and has shown promise in identifying scarring in the heart as well. This will help us not only understand the underlying disease process and risk stratify these patients but also potentially help us develop new targeted therapies that can affect heart muscle scarring. Participants will undergo a baseline MRI scan using this new dye and a plain MRI scan will repeated 12-18 months after to see if there are any changes in the process.",[26,27,28,29,30,31,32],"Heart Failure With Preserved Ejection Fraction","Hypertrophic Cardiomyopathy","Cardiac Sarcoidosis","Hypertensive Heart Disease","Tako Tsubo Cardiomyopathy","Arrhythmogenic Right Ventricular Cardiomyopathy 1","Myocarditis","RECRUITING","2025-08-18",{"date":36,"type":37},"2025-08-19","ACTUAL",{"date":39,"type":37},"2023-05-01",{"date":41,"type":22},"2028-01-01",{"name":43,"class":44},"University of Edinburgh","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":54,"targetDuration":56,"studyType":23,"phases":4,"briefSummary":57,"conditions":58,"keywords":59,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":70,"locationsCount":45},"100556387","hypertensive-heart-disease-in-dr-congo-100556387","NCT06524440","Hypertensive Heart Disease in DR Congo","Comorbidities and the Management of Hypertensive Heart Disease in a Low-Resource Setting: A Cross-Sectional Study","Inclusion Criteria:\n\n* Patients is 18 year or older\n* Patient is diagnosed with hypertensive heart disease\n\nExclusion Criteria:\n\n* Patient is not 18 year or older\n* Patient is not diagnosed with hypertensive heart disease","18 Years",{"count":55,"type":22},400,"1 Day","In this Cross-sectional study, we will analyzed data from a tertiary referral Congolese hospital to find whether or not Congolese patients with hypertensive heart disease have multiple comorbid conditions. Will report on the management and outcomes of the patients.",[29],[60,61,62,63],"Comorbidities","Democratic Republic of Congo","Hypertensive heart disease","Management","2024-07-24",{"date":66,"type":37},"2024-07-29",{"date":68,"type":22},"2024-07-26",{"date":66,"type":22},{"name":71,"class":44},"Association of Future African Neurosurgeons, Yaounde, Cameroon",{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":79,"enrollmentInfo":80,"targetDuration":4,"studyType":82,"phases":83,"briefSummary":85,"conditions":86,"keywords":89,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":4},"100515686","impact-of-renal-denervation-in-patients-with-coronary-microvascular-dysfunction-study-design-and-rationale-100515686","NCT05994729","Impact of Renal Denervation in Patients With Coronary Microvascular Dysfunction: Study Design and Rationale","IMPRESSION","Rul-in Phase Inclusion Criteria:\n\n* Non obstructive stable coronary artery disease (CAD) on invasive coronary angiography (defined as the absence of either \\>50% angiographic stenosis or any flow limiting lesion on functional evaluation)\n* Suspected diagnosis of difficult to control\u002F resistant hypertension for which renal denervation by radiofrequency ablation with Spyral Symplicity 3 could be considered.\n\nRule-in Phase Exclusion Criteria:\n\n* Initiation of either nitrates, beta-blocker or calcium channel blocker less than 30 days before the end of the rule-in phase\n* Physiological assessment performed during first medical contact documenting preserved coronary microvascular function\n* Physiological assessment performed at the \"first contact\" hospitalization followed by modification of medical therapy during the rule-in phase, before RDN\n* Acceptable blood pressure control after medical treatment optimization\n* Identification of secondary causes of hypertension\n* Renal artery anatomy not suitable for RDN\n* Ejection fraction below 30%\n* Life expectancy below 1 year\n* Indication to cardiac surgery\n* Adenosine allergy\n* Pregnancy\n* Large necrotic area documented by either MRI, SPECT or combination of ECG signs + Echocardiographic images.\n* Hemodynamic instability\n* Refuse to sign informed consent\n* Age below 18 or above 80\n\nStudy Phase Inclusion Criteria:\n\n* Having coronary microvascular dysfunction documented by invasive functional assessment (IMR\\>25 and or CFR \\\u003C 2)\n* Fulfilling all the rule-in phase inclusion criteria without any rule-in phase exclusion criteria\n\nStudy Phase Exclusion Criteria:\n\n* Refuse to sign informed consent\n* Evidence of newly detected obstructive CAD on invasive coronary angiography performed 6 months after RDN","80 Years",{"count":81,"type":22},87,"INTERVENTIONAL",[84],"NA","Long-standing hypertension may cause an impairment in microvascular coronary circulation which is involved in many different cardiac conditions. Renal denervation (RDN) has been successfully proven as a valuable and powerful therapeutic choice to consider for patients with resistant hypertension; moreover this procedure looks promising in other cardiac disease such as heart failure and atrial fibrillation, given its ability to downregulate sympathetic nervous system The aim of this study is to explore the effect of renal denervation and blood pressure control on coronary microvascular dysfunction.\n\nThis is a multicenter, prospective, non randomized, open-label, interventional study. Consecutive patients with resistant hypertension, non obstructive coronary artery disease and documented microvascular dysfunction will be enrolled. Patients will undergo renal denervation by Spyral Symplicity 3 and re-assessment of coronary microvascular function 12 months after the procedure. Primary endpoint will be the difference in average index of microcirculatory resistance value.",[87,88,29],"Coronary Microvascular Dysfunction","Resistant Hypertension",[90,91],"MVD","HHD","NOT_YET_RECRUITING","2023-10-22",{"date":95,"type":37},"2023-10-24",{"date":97,"type":22},"2024-01-01",{"date":99,"type":22},"2026-12-31",{"name":101,"class":44},"Aurelia Hospital"]